News

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq:…

1 year ago

iZafe Group Announces the Appointment of Nomination Committee

STOCKHOLM, SE / ACCESSWIRE / November 13, 2023 / iZafe Group (STO:IZAFE-B) iZafe Group AB (publ.) is pleased to announce…

1 year ago

BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis

VANCOUVER, BC / ACCESSWIRE / November 13, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to…

1 year ago

BIGVITA Announces its New Product Line of Supplements with Specific Functions

This Revolution in the Health & Wellness Industry will Help People Get Exactly what they are Looking For instead of…

1 year ago

Long-term Survival Data from Longeveron’s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association

Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct…

1 year ago

Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine

Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated…

1 year ago

The Virtual Trip Showcases Veterans Sessions from Psychedelic Science 2023 in Honor of Veterans Day

Psychedelic Science 2023 was the breakthrough conference in psychedelics over 5 days in June 2023 in Denver, CO. Hosted by…

1 year ago

Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on…

1 year ago

Recor Medical Announces U.S. Launch and First Commercial Cases of Paradise Ultrasound Renal Denervation Therapy

Innovative new treatment option for patients with uncontrolled hypertension now available in the United StatesPALO ALTO, Calif.--(BUSINESS WIRE)--Recor Medical, Inc.…

1 year ago